Smart-Money SignalNeutral · 55/100— Insiders are net buyers over 90 days ($7.5M, 1 buy vs 0 sales)
Net Income-$2.9M
EPS$-2.63
Market Cap$6.6M
Price Performance
Historical data including institutional events
Company Profile
S
Stephan Jackman
CEO & Executive Director
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.
Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimerâs, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patientâs immunological system to combat Alzheimerâs disease.
Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
